Virtual Library
Start Your Search
K. Okuda
Author of
-
+
P3.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 226)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.08-033 - Expression of Excision Repair Cross-Complementation Group 1 and Class III β-Tubulin in Thymic Carcinoma (ID 1295)
09:30 - 09:30 | Author(s): K. Okuda
- Abstract
Background:
Thymic carcinoma is a rare mediastinum malignant tumor based on thymic epithelial cells. The complete surgical resection is considered as a best treatment for thymic carcinoma. However, except completely resected cases, the effective therapy has not been established for the advanced or relapsed thymic carcinoma. The expression of excision repair cross-complementation group 1 (ERCC1) and class Ⅲ β-tubulin (TUBB3) protein are respectively expected as an indicator for the anticancer activity of the platinum-based and taxane-based chemotherapy.
Methods:
We examined the expression of ERCC1 and TUBB3 protein in 40 thymic carcinoma patients who underwent either the surgical resection or the core-needle biopsy. We also evaluated the expression of ERCC1 and TUBB3 protein in 50 patients who underwent the curative resection for the non-small cell lung cancer (NSCLC). We investigated whether the expression of ERCC1 and TUBB3 protein were associated with some overall survival and clinic-pathological factors of thymic carcinoma patients.
Results:
The expression of ERCC1 and TUBB3 protein were positive in eight cases (20%) in thymic carcinoma patients. ERCC1 was expressed in twenty-one cases (42%), while TUBB3 was in twenty-seven cases (54%) in the fifty NSCLC patients. In all thymic carcinoma cases, the 3 year-survival was 67.3%. Only complete resection was associated with the better prognosis (p=0.0341). Other clinico-pathological factors including the expression of ERCC1 and TUBB3 protein showed no effect on the overall survival.
Conclusion:
High expression of ERCC1 and TUBB3 might be associated with resistance to the platinum-based and taxane-based chemotherapy. Our results suggest a possibility of better antitumor effects of the platinum-based and taxane-based chemotherapy on the thymic carcinoma patients.
